Patents by Inventor John W. Erickson

John W. Erickson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180256534
    Abstract: Compositions and methods of treating depression infections are provided. More particularly, compositions including a combination of ketamine and a cytochrome p450 enzyme inhibitor are provided. Methods of using the compositions for treatment of depression, including treatment-resistant or treatment-refractory depression, are provided. Compositions and methods of treating depression infections are provided. More particularly, compositions including a combination of ketamine and a cytochrome p450 enzyme inhibitor are provided. Methods of using the compositions for treatment of depression, including treatment-resistant or treatment-refractory depression, are provided.
    Type: Application
    Filed: March 5, 2018
    Publication date: September 13, 2018
    Inventor: John W. ERICKSON
  • Patent number: 9889115
    Abstract: The present invention provides an assay for determining the biochemical fitness of a biochemical species in a mutant replicating biological entity relative to its predecessor. The present invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The present invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: February 13, 2018
    Assignees: Board of Trustees of the University of Illinois, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: John W. Erickson, Sergei V. Gulnik, Hiroaki Mitsuya, Arun E. Ghosh
  • Publication number: 20150284352
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Application
    Filed: February 9, 2015
    Publication date: October 8, 2015
    Inventors: Michael EISSENSTAT, Dehui DUAN, Sergei GULNIK, John W. Erickson
  • Patent number: 8952056
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Grant
    Filed: February 23, 2009
    Date of Patent: February 10, 2015
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan, Sergi Gulnik, John W. Erickson
  • Patent number: 8673970
    Abstract: Compositions and methods of treating viral infections are provided. More particularly, compositions including a combination of protease inhibitors and cytochrome p450 enzyme inhibitors are provided. Methods of using the compositions for treatment of diseases or disorders caused by a virus such as HIV infections are also provided.
    Type: Grant
    Filed: February 23, 2009
    Date of Patent: March 18, 2014
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan, John W. Erickson
  • Publication number: 20140011815
    Abstract: The present invention provides an assay for determining the biochemical fitness of a biochemical species in a mutant replicating biological entity relative to its predecessor. The present invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The present invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy.
    Type: Application
    Filed: July 2, 2013
    Publication date: January 9, 2014
    Inventors: John W. Erickson, Sergei V. Gulnik, Hiroaki Mitsuya, Arun E. Ghosh
  • Patent number: 8597876
    Abstract: Disclosed is a method of treating human immunodeficiency virus (HIV) infection in an antiretroviral treatment-experienced mammal, which involves administering to the mammal an effective amount of a compound of the formula: or a pharmaceutically acceptable salt, a prodrug, or an ester thereof, or a pharmaceutically acceptable composition of the compound, the salt, the prodrug, or the ester thereof, wherein A, X, Q, W, m, and R2-R6 are as defined herein.
    Type: Grant
    Filed: October 11, 2007
    Date of Patent: December 3, 2013
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Board of Trustees of the University of Illinois
    Inventors: John W. Erickson, Sergei V. Gulnik, Hiroaki Mitsuya, Arun K. Ghosh
  • Patent number: 8366492
    Abstract: A terminal reversing block mounts to a standard electrical disconnect device such as a circuit breaker or a pullout switch. The disconnect device has a housing which defines a cavity that faces in one direction for receiving a cable. Front and rear contacts are in the housing, one of which extends into the cavity for engagement with a cable. A terminal reversing block has a housing with at least one pocket which faces in a direction other than the opposite of the direction in which the disconnect device's cavity faces. A terminal collar disposed in the terminal reversing block pocket is engageable with a cable inserted into the pocket. A terminal in the reversing block has a mating portion and a connecting portion. The connecting portion engages the terminal collar. The mating portion engages one of the front and rear contacts of the electrical disconnect device.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: February 5, 2013
    Assignee: Boltswitch, Inc.
    Inventors: John W. Erickson, James A. Erickson, John Walter Erickson
  • Publication number: 20110166061
    Abstract: The present invention is concerned with This invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.
    Type: Application
    Filed: April 26, 2010
    Publication date: July 7, 2011
    Applicant: CONJUCHEM BIOTECHNOLOGIES, INC.
    Inventors: John W. Erickson, Dominique P. Bridon, Martin Robitaille, Grant A. Krafft, Dong Xie, Elena Afonina, Jun Liang, Sandra De Meyer
  • Publication number: 20110147175
    Abstract: A terminal reversing block mounts to a standard electrical disconnect device such as a circuit breaker or a pullout switch. The disconnect device has a housing which defines a cavity that faces in one direction for receiving a cable. Front and rear contacts are in the housing, one of which extends into the cavity for engagement with a cable. A terminal reversing block has a housing with at least one pocket which faces in a direction other than the opposite of the direction in which the disconnect device's cavity faces. A terminal collar disposed in the terminal reversing block pocket is engageable with a cable inserted into the pocket. A terminal in the reversing block has a mating portion and a connecting portion. The connecting portion engages the terminal collar. The mating portion engages one of the front and rear contacts of the electrical disconnect device.
    Type: Application
    Filed: December 21, 2010
    Publication date: June 23, 2011
    Applicant: Boltswitch, Inc.
    Inventors: John W. Erickson, James A. Erickson, John Walter Erickson
  • Publication number: 20110112137
    Abstract: Compositions and methods of treating viral infections are provided. More particularly, compositions including a combination of protease inhibitors and cytochrome p450 enzyme inhibitors are provided. Methods of using the compositions for treatment of diseases or disorders caused by a virus such as HIV infections are also provided.
    Type: Application
    Filed: February 23, 2009
    Publication date: May 12, 2011
    Applicant: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan, John W. Erickson
  • Publication number: 20110098237
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Application
    Filed: February 23, 2009
    Publication date: April 28, 2011
    Applicant: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan, Sergi Gulnik, John W. Erickson
  • Patent number: 7741453
    Abstract: The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: June 22, 2010
    Assignee: Conjuchem Biotechnologies, Inc.
    Inventors: John W. Erickson, Dominique P. Bridon, Martin Robitaille, Grant A. Krafft, Dong Xie, Elena Afonina, Jun Liang, Sandra DeMeyer
  • Publication number: 20100009935
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Application
    Filed: July 16, 2009
    Publication date: January 14, 2010
    Applicant: SEQUOIA PHARMACEUTICALS
    Inventors: John W. Erickson, Michael Eissenstat, Abelardo Silva, Sergei Gulnik
  • Patent number: 7470506
    Abstract: The present invention provides an assay for determining the biochemical fitness of a biochemical species in a mutant replicating biological entity relative to its predecessor. The present invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The present invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy.
    Type: Grant
    Filed: June 23, 1999
    Date of Patent: December 30, 2008
    Assignees: The United States of America as represented by the Department of Health and Human Services, Board of Trustees of the University of Illinois
    Inventors: John W. Erickson, Sergei V. Gulnik, Hiroaki Mitsuya, Arun K. Ghosh
  • Patent number: 7320878
    Abstract: The present invention concerns a further development and use of biological assays to determine the amount or concentration of an active ingredient present in a sample. The enzyme assay of the present invention determines the amount or concentration of protease inhibitors, including retroviral protease inhibitors such as HIV inhibitors.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: January 22, 2008
    Assignees: Tibotec Pharmaceuticals, Ltd., Aaron Diamond Aids Research Center, The Rockefeller University
    Inventors: Sergei Gulnik, Betty Yu, John W Erickson, Martin Markowitz
  • Patent number: 7285566
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: October 23, 2007
    Inventors: John W. Erickson, Michael Eissenstat, Abelardo Silva, Sergei Gulnik
  • Patent number: 7157495
    Abstract: Compositions comprising bis-tetrahydrofuran benzodioxyolyl sulfonamide compounds that are surprisingly effective protease inhibitors and a second antiretroviral compound are disclosed. Methods of inhibiting retrovirus proteases, in particular multi-drug resistant retrovirus proteases, methods of treating or preventing infection or disease associated with retrovirus infection in a mammal, and methods of inhibiting viral replication are also disclosed.
    Type: Grant
    Filed: June 25, 2003
    Date of Patent: January 2, 2007
    Assignees: Tibotec Pharmaceuticals, Ltd., The United States of America as represented by the Department of Health and Human Services
    Inventors: Guangyang Wang, Michael Eissenstat, John W. Erickson, Piet T. B. P. Wigerinck
  • Patent number: 7151163
    Abstract: The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates and pharmaceutical compositions containing those peptides and conjugates that block fusion of a coronavirus, such as the SARS virus, to a target cell. This blocking mechanism prevents or treats a coronavirus infection, such as a SARS infection, in a subject, such as a human subject.
    Type: Grant
    Filed: April 28, 2004
    Date of Patent: December 19, 2006
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: John W. Erickson, Abelardo Silva
  • Patent number: 7132420
    Abstract: The present invention provides an aspartic proteinase-inhibiting compound of the formula: wherein a, b, c, d, and e, can be the same or different and each are R7, OR7, SR7, NR7R8, NHCOR7, CO2R7, CN, NO2, NH2, N3, or a halogen, wherein R7 and R8 are independently H or an alkyl. Substituents R1 or R2 are each H or an alkyl. Substituent R3 is a straight chain or branched alkyl, alkenyl, or alkynyl substituent, or is a cycloalkyl. Substituent A is OH, NH2, or SH. Further provided are pharmaceutical compositions, which include a therapeutically effective amount of at least one of the foregoing compounds, and therapeutic methods of using the foregoing compounds.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: November 7, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ramnarayan S. Randad, John W. Erickson, Michael A. Eissenstat, Lucyna Lubkowska